Treatment of Fabry Nephropathy: A Literature Review
Open Access
Abstract
Fabry disease is an X-linked inherited lysosomal storage disorder with a deficiency of α-galactosidase A activity, which results in the intracellular accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids in various organs. Fabry nephropathy is one of the major complications of Fabry disease, and kidney damage is often related to cardiovascular disease and mortality. The treatment of Fabry nephropathy thus helps prolong life expectancy. Two treatment options for Fabry nephropathy and cardiopathy are now commercially available: enzyme replacement therapy (agalsidase α agalsidase β, and a biosimilar of agalsidase β) and pharmacological chaperone therapy (migalastat). In this review, we summarize the efficacy of these treatment options for Fabry nephropathy with respect to renal function, proteinuria, and renal pathological findings. We also describe the importance of adjunctive therapy for Fabry nephropathy.Keywords
This publication has 57 references indexed in Scilit:
- Newborn screening for Fabry disease in Japan: prevalence and genotypes of Fabry disease in a pilot studyJournal of Human Genetics, 2013
- The Effectiveness of Long-Term Agalsidase Alfa Therapy in the Treatment of Fabry NephropathyClinical Journal of the American Society of Nephrology, 2012
- Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiationNephrology Dialysis Transplantation, 2011
- Prognostic Indicators of Renal Disease Progression in Adults with Fabry DiseaseClinical Journal of the American Society of Nephrology, 2010
- Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onsetGLAmutation c.936+919G>A (IVS4+919G>A)Human Mutation, 2009
- Agalsidase Alfa and Kidney Dysfunction in Fabry DiseaseJournal of the American Society of Nephrology, 2009
- Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapyNephrology Dialysis Transplantation, 2009
- Agalsidase Alfa Slows the Decline in Renal Function in Patients with Fabry DiseaseAmerican Journal of Nephrology, 2008
- Weekly Enzyme Replacement Therapy May Slow Decline of Renal Function in Patients with Fabry Disease Who Are on Long-Term Biweekly DosingJournal of the American Society of Nephrology, 2007
- High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*The American Journal of Human Genetics, 2006